Open Menu
CLINICAL TRIALS IN WET AMD:

Sozinibercept Phase 3 Clinical Program

BACK

Sozinibercept Phase 3 Clinical Program

Opthea’s Phase 3 clinical trial program is designed to support a broad label and has received Fast Track Designation from the US FDA for the treatment of wet AMD. Sozinibercept has the potential to be approved for use in combination with any anti-VEGF-A for the treatment of wet AMD patients.

CLINICALTRIALS.GOV
CLINICALTRIALS.GOV

Top line results of COAST are expected in early Q2/2025 and ShORe in mid 2025.

Explore our Phase 2b Trial

Sozinibercept Demonstrated Superior Visual Outcomes in our Wet AMD Phase 2b Clinical Trial

View the Sozinibercept Phase 2B Program